Literature DB >> 24994560

Quantitative proteomic analysis reveals metabolic alterations, calcium dysregulation, and increased expression of extracellular matrix proteins in laminin α2 chain-deficient muscle.

Bruno Menezes de Oliveira1, Cintia Y Matsumura2, Cibely C Fontes-Oliveira1, Kinga I Gawlik1, Helena Acosta3, Patrik Wernhoff1, Madeleine Durbeej4.   

Abstract

Congenital muscular dystrophy with laminin α2 chain deficiency (MDC1A) is one of the most severe forms of muscular disease and is characterized by severe muscle weakness and delayed motor milestones. The genetic basis of MDC1A is well known, yet the secondary mechanisms ultimately leading to muscle degeneration and subsequent connective tissue infiltration are not fully understood. In order to obtain new insights into the molecular mechanisms underlying MDC1A, we performed a comparative proteomic analysis of affected muscles (diaphragm and gastrocnemius) from laminin α2 chain-deficient dy(3K)/dy(3K) mice, using multidimensional protein identification technology combined with tandem mass tags. Out of the approximately 700 identified proteins, 113 and 101 proteins, respectively, were differentially expressed in the diseased gastrocnemius and diaphragm muscles compared with normal muscles. A large portion of these proteins are involved in different metabolic processes, bind calcium, or are expressed in the extracellular matrix. Our findings suggest that metabolic alterations and calcium dysregulation could be novel mechanisms that underlie MDC1A and might be targets that should be explored for therapy. Also, detailed knowledge of the composition of fibrotic tissue, rich in extracellular matrix proteins, in laminin α2 chain-deficient muscle might help in the design of future anti-fibrotic treatments. All MS data have been deposited in the ProteomeXchange with identifier PXD000978 (http://proteomecentral.proteomexchange.org/dataset/PXD000978).
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24994560      PMCID: PMC4223487          DOI: 10.1074/mcp.M113.032276

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  67 in total

1.  Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta.

Authors:  K Horiuchi; N Amizuka; S Takeshita; H Takamatsu; M Katsuura; H Ozawa; Y Toyama; L F Bonewald; A Kudo
Journal:  J Bone Miner Res       Date:  1999-07       Impact factor: 6.741

2.  Proteomic assessment of the acute phase of dystrophin deficiency in mdx mice.

Authors:  D Gardan-Salmon; J M Dixon; S M Lonergan; J T Selsby
Journal:  Eur J Appl Physiol       Date:  2011-03-16       Impact factor: 3.078

Review 3.  Pathophysiology of duchenne muscular dystrophy: current hypotheses.

Authors:  Nicolas Deconinck; Bernard Dan
Journal:  Pediatr Neurol       Date:  2007-01       Impact factor: 3.372

4.  Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy.

Authors:  Jachinta E Rooney; Jolie R Knapp; Bradley L Hodges; Ryan D Wuebbles; Dean J Burkin
Journal:  Am J Pathol       Date:  2012-02-06       Impact factor: 4.307

5.  Distinct roles for laminin globular domains in laminin alpha1 chain mediated rescue of murine laminin alpha2 chain deficiency.

Authors:  Kinga I Gawlik; Mikael Akerlund; Virginie Carmignac; Harri Elamaa; Madeleine Durbeej
Journal:  PLoS One       Date:  2010-07-19       Impact factor: 3.240

6.  Proteomic analysis of mdx skeletal muscle: Great reduction of adenylate kinase 1 expression and enzymatic activity.

Authors:  Yue Ge; Mark P Molloy; Jeffrey S Chamberlain; Philip C Andrews
Journal:  Proteomics       Date:  2003-10       Impact factor: 3.984

7.  Mutation in dystrophin-encoding gene affects energy metabolism in mouse myoblasts.

Authors:  Marta Onopiuk; Wojciech Brutkowski; Katarzyna Wierzbicka; Sylwia Wojciechowska; Joanna Szczepanowska; Jan Fronk; Hanns Lochmüller; Dariusz C Górecki; Krzysztof Zabłocki
Journal:  Biochem Biophys Res Commun       Date:  2009-06-13       Impact factor: 3.575

8.  Experimental and statistical considerations to avoid false conclusions in proteomics studies using differential in-gel electrophoresis.

Authors:  Natasha A Karp; Paul S McCormick; Matthew R Russell; Kathryn S Lilley
Journal:  Mol Cell Proteomics       Date:  2007-05-17       Impact factor: 5.911

9.  Bcl-2 inhibits the innate immune response during early pathogenesis of murine congenital muscular dystrophy.

Authors:  Sheila Jeudy; Katherine E Wardrop; Amy Alessi; Janice A Dominov
Journal:  PLoS One       Date:  2011-08-05       Impact factor: 3.240

10.  Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages.

Authors:  Sarina Meinen; Patrizia Barzaghi; Shuo Lin; Hanns Lochmüller; Markus A Ruegg
Journal:  J Cell Biol       Date:  2007-03-26       Impact factor: 10.539

View more
  12 in total

1.  Purification of sarcoplasmic reticulum vesicles from horse gluteal muscle.

Authors:  Joseph M Autry; Christine B Karim; Mariana Cocco; Samuel F Carlson; David D Thomas; Stephanie J Valberg
Journal:  Anal Biochem       Date:  2020-09-19       Impact factor: 3.365

2.  212th ENMC International Workshop: Animal models of congenital muscular dystrophies, Naarden, The Netherlands, 29-31 May 2015.

Authors:  M Saunier; C G Bönnemann; M Durbeej; V Allamand
Journal:  Neuromuscul Disord       Date:  2016-02-15       Impact factor: 4.296

3.  Merosin deficient congenital muscular dystrophy type 1A: An international workshop on the road to therapy 15-17 November 2019, Maastricht, the Netherlands.

Authors:  Hubert J M Smeets; Bram Verbrugge; Pierre Springuel; Nicol C Voermans
Journal:  Neuromuscul Disord       Date:  2021-05-01       Impact factor: 4.296

4.  Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells.

Authors:  Cibely C Fontes-Oliveira; Maarten Steinz; Peter Schneiderat; Hindrik Mulder; Madeleine Durbeej
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

5.  Global Proteome Changes in the Rat Diaphragm Induced by Endurance Exercise Training.

Authors:  Kurt J Sollanek; Jatin G Burniston; Andreas N Kavazis; Aaron B Morton; Michael P Wiggs; Bumsoo Ahn; Ashley J Smuder; Scott K Powers
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

6.  Exploratory Profiling of Urine MicroRNAs in the dy2J/dy2J Mouse Model of LAMA2-CMD: Relation to Disease Progression.

Authors:  Bernardo Moreira Soares Oliveira; Kinga I Gawlik; Madeleine Durbeej; Johan Holmberg
Journal:  PLoS Curr       Date:  2018-08-27

7.  Custom 4-Plex DiLeu Isobaric Labels Enable Relative Quantification of Urinary Proteins in Men with Lower Urinary Tract Symptoms (LUTS).

Authors:  Tyler Greer; Ling Hao; Anatoliy Nechyporenko; Sanghee Lee; Chad M Vezina; Will A Ricke; Paul C Marker; Dale E Bjorling; Wade Bushman; Lingjun Li
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

Review 8.  At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients?

Authors:  Kinga I Gawlik
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

9.  Effects of metformin on congenital muscular dystrophy type 1A disease progression in mice: a gender impact study.

Authors:  Cibely C Fontes-Oliveira; Bernardo M Soares Oliveira; Zandra Körner; Vahid M Harandi; Madeleine Durbeej
Journal:  Sci Rep       Date:  2018-11-02       Impact factor: 4.379

10.  Early skeletal muscle pathology and disease progress in the dy3K/dy3K mouse model of congenital muscular dystrophy with laminin α2 chain-deficiency.

Authors:  Kinga I Gawlik; Zandra Körner; Bruno M Oliveira; Madeleine Durbeej
Journal:  Sci Rep       Date:  2019-10-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.